Aurobindo Pharma to Manufacture and Supply Long-Acting HIV Treatment Across 133 Countries

Hyderabad, July 15 (Maxim News): In a major boost for global healthcare access, Hyderabad-based Aurobindo Pharma has announced that it will manufacture and distribute the long-acting injectable HIV treatment drug, cabotegravir (CAB LA), across 133 countries. The development comes under an expanded voluntary licensing agreement between the Medicines Patent Pool (MPP) and ViiV Healthcare.

Here To Join Us On WhatsApp

This strategic agreement will allow Aurobindo to supply CAB LA for both prevention and treatment of HIV, offering an alternative to daily oral medication with a single injection administered every one or two months. The drug is considered a breakthrough in HIV treatment due to its long-acting properties and potential to improve patient adherence.

In a statement, Aurobindo Pharma Vice Chairman and Managing Director K. Nithyananda Reddy said, “We are privileged to be part of this sub-license expansion from MPP and ViiV. This is a significant and timely step towards increasing access to advanced long-acting HIV treatment in low- and middle-income countries (LMICs).”

Here To Join Us On WhatsApp

Aurobindo will manufacture and supply the drug in public and private markets across all least-developed, low-income, lower-middle-income, and Sub-Saharan African countries, as well as regions where ViiV does not hold patent rights for cabotegravir.

The announcement follows updated World Health Organization (WHO) guidelines, which recommend the combination of long-acting injectable cabotegravir and rilpivirine as a treatment option for HIV. Previously, CAB LA was only approved for pre-exposure prophylaxis (PrEP) to prevent HIV infection.

Here To Join Us On WhatsApp

The move also reflects a growing effort to expand equitable access to advanced HIV treatments, especially in resource-limited settings. ViiV Healthcare — a global HIV specialist company majority owned by GSK, with Pfizer and Shionogi as stakeholders — has partnered with MPP to promote wider availability of this crucial medication.

“Aurobindo remains committed to leveraging its robust global supply network to make this life-saving long-acting therapy widely accessible and affordable,” Reddy added.

The inclusion of private sector markets in royalty-bearing countries is being hailed as a critical step toward bridging the treatment gap between high-income and developing nations, ensuring broader access to modern, effective HIV care.

Next Story:

Now you can get the latest stories from Indtoday on Telegram every day. Click the link to subscribe.  Click to follow Indtoday’s Facebook page, Twitter, and Instagram. For all the latest Hyderabad News update